Addressing solid tumours and the upcoming clinical trial of natural killer (NK) cell therapy for ovarian cancer
Cartherics: An Innovative Company Developing Cellular Immunotherapy Cancer Treatments
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Pulse 2.0 discussing Cartherics’ innovative approach to using stem cells to develop new cancer therapies. Alan’s leadership and expertise underscore the company’s commitment to advancing cancer treatment and improving outcomes for patients. Read the article here: https://pulse2.com/cartherics-prof-alan-trounson-profile/
The first baby from a frozen embryo turns 40!
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by Barbara Barkhausen, a German speaking, Asia-Pacific Correspondent for a variety of German, Austrian and Swiss newspapers. Barbara’s article, translated below, was published in a number of European newspapers, highlighting that the first baby born from a frozen embryo is now 40 years old – a result […]
Emergence of antibody-drug conjugates (ADCs) as the “hot, new technology” (and potential lessons for cell therapy companies)
Ian Nisbet, PhD
Chief Operating Officer, Cartherics Pty Ltd
As published in pharmaphorum
Background
The recent acquisition of ImmunoGen by AbbVie, which followed the earlier acquisition of Seagen by Pfizer, has brought renewed attention to Antibody-Drug Conjugates (ADCs), highlighting their potential in cancer therapy [1, 2]. This development serves as an opportunity for companies to reflect on the […]
Cartherics enters into Collaborative Research Agreement with TiCARos
Melbourne, Australia, 2 April 2024 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered a collaborative research agreement with TiCARos Co Ltd (“TiCARos”) to assess its proprietary CLIP-CAR technology in Cartherics’ induced pluripotent stem cell (iPSC)-derived natural killer […]
Cartherics executes Option Agreement with The Ohio State University
TISSUE FACTOR AS A NOVEL TARGET FOR CAR-NK CELLS
Melbourne, Australia, 20 March 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has executed an option agreement to evaluate intellectual property (IP) from The Ohio State University (Ohio […]
Cartherics: Leading the Charge in Immunotherapy for Solid Tumours
At Emergence 2024, Cartherics’ COO, Dr Ian Nisbet was interviewed by Wholesale Investor. In the interview, Ian discusses the company’s cutting-edge strategies in combating solid tumours through cell-based immunotherapy. From leveraging stem cells to navigating regulatory pathways and entering clinical trials, Cartherics is on a mission to redefine cancer treatment. This interview highlights the challenges, […]
Teal Ribbon Day: Raising awareness for ovarian cancer
Each year in Australia around 1815 women are diagnosed with ovarian cancer. In most cases the cancer will be diagnosed at an advanced stage, where it is very difficult to treat.
To help raise awareness for ovarian cancer, Cartherics hosted a Teal Ribbon Day afternoon tea. Our Teal Tea provided a great opportunity to bring people […]
Cartherics to present and exhibit at Emergence 2024
Cartherics is pleased to announce that it will be attending Emergence 2024 – The Era of Abundance investment conference at the Hilton Sydney next week.
The company’s CEO, Prof. Alan Trounson AO, will be presenting at 11:14 am on Wednesday 28th February. His presentation will discuss:
- Cartherics’ breakthrough approach to treating solid tumours.
- How CTH-401, […]
Cartherics’ CEO discusses the future of solid tumour therapy
Cartherics’ CEO, Prof. Alan Trounson AO was recently interviewed by Wholesale Investor to discuss the company’s latest developments and the future of solid tumour therapy. In the interview Alan, shares insights into Cartherics’ cutting-edge technology, including the use of gene-edited natural killer (NK) cells and the strategic approach to leveraging a robust IP portfolio for […]
